As part of his election to the board, Sullivan will receive $11,667 and a stock award of PerkinElmer common stock with a fair market value of $16,667, the company said in a document filed with the US Securities and Exchange Commission. He will also receive an initial one-time stock option grant of 10,000 shares of PerkinElmer stock.
Patrick Sullivan has been elected to PerkinElmer’s board, the company said this week. Sullivan is executive chairman of Hologic. He was also chairman, president, and CEO of Cytyc, which merged with Hologic in October. Previously he had sales and marketing positions with Abbott Laboratories.